Current status of developments in the field of respiratory syncytial virus vaccines
Respiratory syncytial virus (RSV) is the leading cause of upper respiratory tract infections in children and the elderly. The only specific treatment approved for RSV is the monoclonal antibody Palivizumab for passive immunoprophylaxis in high-risk infants. Sixty years after the virus was discovered...
Saved in:
| 主要作者: | |
|---|---|
| 格式: | Article |
| 語言: | 俄语 |
| 出版: |
Central Research Institute for Epidemiology
2025-05-01
|
| 叢編: | Журнал микробиологии, эпидемиологии и иммунобиологии |
| 主題: | |
| 在線閱讀: | https://microbiol.crie.ru/jour/article/viewFile/18831/1595 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|